Cargando…
A feasibility and safety study of afamelanotide in acute stroke patients – an open label, proof of concept, phase iia clinical trial
BACKGROUND: Neuroprotective agents have the potential to improve the outcomes of revascularisation therapies in acute ischemic stroke patients (AIS) and in those unable to receive revascularisation. Afamelanotide, a synthetic α-melanocyte stimulating hormone analogue, is a potential novel neuroprote...
Autores principales: | Stanislaus, Vimal, Kam, Anthony, Murphy, Lily, Wolgen, Philippe, Walker, Gill, Bilbao, Pilar, Cloud, Geoffrey C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10373257/ https://www.ncbi.nlm.nih.gov/pubmed/37496004 http://dx.doi.org/10.1186/s12883-023-03338-9 |
Ejemplares similares
-
Advances in the management of erythropoietic protoporphyria – role of afamelanotide
por: Lane, Ashley M, et al.
Publicado: (2016) -
Afamelanotide Is Associated with Dose-Dependent Protective Effect from Liver Damage Related to Erythropoietic Protoporphyria
por: Minder, Anna-Elisabeth, et al.
Publicado: (2023) -
Beyond pigmentation: signs of liver protection during afamelanotide
treatment in Swiss patients with erythropoietic protoporphyria, an observational
study
por: Minder, Anna-Elisabeth, et al.
Publicado: (2021) -
Seamless phase IIa/IIb adaptive design with the same primary endpoint for proof of concept and dose finding
por: Yuan, Jiacheng, et al.
Publicado: (2018) -
Open‐label, proof‐of‐concept study of brexanolone in the treatment of severe postpartum depression
por: Kanes, Stephen J., et al.
Publicado: (2017)